This year, China has approved more than ten innovative drugs, and the innovative drug ETF Tianhong (517380) has a trading volume exceeding 5 million yuan. Institutions: The sector is experiencing a dual resonance of fundamentals and sentiment

This year, China has approved more than ten innovative drugs, and the innovative drug ETF Tianhong (517380) has a trading volume exceeding 5 million yuan. The three major indices have mixed performances, with the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 Index down 1.18%. The innovative drug ETF is the only ETF tracking this index, covering the entire industry chain. Data from the National Medical Products Administration shows that 13 innovative drugs have been approved in the first four months of this year, with a total transaction volume of over 60 billion USD for innovative drug licensing deals. Huayuan Securities believes that the innovative drug sector is experiencing a dual resonance of fundamentals and sentiment, with breakthroughs in AI pharmaceutical technology and the international expansion of Chinese innovative drugs creating a dual resonance